May/June 2025 | Features
Beyond Complement: Emerging Therapeutics for Dry AMD
Targeting inflammation, mitochondrial health, and neuroprotection.
Aumer Shughoury, MD, and Thomas A. Ciulla, MD, MBA
May/June 2025 | Features
FDA Guidance: What it Means for AMD Trials
Industry leaders discuss the shifts in clinical trial designs and their recent interactions with the FDA.
Nadia K. Waheed, MD, MPH; Ramiro Ribeiro, MD, PhD; Victor Chong, MD, MBA, FARVO; Lanita Scott, MD; and David J. Tanzer, MD
January/February 2024 Insert
When to Use Thermal or Subthreshold Laser?
Victor Chong, MD, MBA, FRCOphth
November/December 2016 | business Of Retinainnovations In Retina
Targeting the Visual Cycle: Dry AMD and Stargardt Disease
The visual cycle could be the crucible for treating two important degenerative eye diseases.
Aron Shapiro; David Hollander, MD, MBA; and Andrew Hertsenberg, PhD
July/August 2015
Profile of a Potential Treatment for Geographic Atrophy
An in-depth look at a complement-targeted therapy.
Karen Roman, Editor-in-Chief
